



Effective 7/1/2026

Lines Of Business Commercial, Medicaid, PEIA, Self-Funded/ASO

Genetic, Pharmacogenetic, and Pharmacodynamic Testing for Diagnosis and Management of Behavioral Health Conditions

PURPOSE:

This policy addresses emerging technology surrounding genetic, pharmacogenetic, and pharmacodynamic testing performed in relation to a behavioral health disorder in order to guide the selection of medication for such disorders. Providers are encouraged to check eligibility and benefits prior to submitting any requests for genetic, pharmacogenetic, and pharmacodynamic testing as some plans limit certain types of testing, such as genetic testing.

This policy is not intended for the Medicare lines of business. The Health Plan will utilize InterQual® Guidelines or the relevant NCD, or LCD as appropriate.

DEFINITIONS

CLIA - The Clinical Laboratory Improvement Amendments

COVERAGE POLICY:

Behavioral health conditions considered in this policy include schizophrenia and related psychotic disorders, bipolar and related disorders, depressive disorders, anxiety disorders, hyperactivity disorders, obsessive-compulsive and related disorders, and substance-related and addictive disorders.

FDA approval and/or clearance alone is not an indication of coverage. For the tests listed in this policy, at this time the American Psychiatric Association (APA), American Academy of Child and Adolescent Psychiatrists (AACAP), and the American Academy of Family Physicians (AAFP) consider any commercially available genetic, pharmacogenetic, and pharmacodynamic test being performed in relation to a behavioral health disorder as having a lack of sufficient peer review literature or evidence based guidelines available to determine the value of the testing regarding clinical efficacy, safety, or applicability to clinical practice, and to what extent a specific test supports clinical decision making or has demonstrated a definitive positive impact

on clinical outcomes.

Changes may occur to coverage/benefits of WV Medicaid/Mountain Health Trust plans before this list is updated. If the coverage criteria in the below list conflicts with the relevant WV Medicaid/Mountain Health Trust document, that document will control the application of services.

Genetic testing for diagnosis and management of behavioral health disorders is considered investigational in all situations, including but not limited to the following:

- To confirm a diagnosis of a behavioral health disorder in an individual with symptoms.
- To predict future risk of a behavioral health disorder in an asymptomatic individual.
- To inform the selection or dose of medications used to treat behavioral health disorders, including but not limited to selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and antipsychotic drugs.

The listings below are not intended to be all inclusive. Please check with The Health Plan regarding precertification requirements if a genetic, pharmacogenetic, and pharmacodynamic test being performed in relation to a behavioral health disorder is not found listed in this policy or on the Prior Authorization List on the Internet.

EXCLUDED OR NON-COVERED TESTS

When used for depression, anxiety, ADHD, and other psychiatric disorders.

Aura Genetics Pharmacogenomics (PGx) Test (Aura Genetics) 81418 (comprehensive), 81225 (CYP2C19)

ComplyRX urine test, (Claro Labs) 0093U

EffectiveRX Comprehensive Panel (RCA Laboratory Services LLC d/b/a GENETWORx) 0438U

Genecept Assay, (Genomind®, Inc) 81418, 81479

Genomind® Pharmacogenetics Report (Genomind®, Inc) 0423U

Genomind® Professional PGx Express™ CORE (Genomind®, Inc) 0175U

GeneSight® ADHD (Assurex Health, Inc, Myriad Genetics, Inc) 0345U

GeneSight® Analgesic (Assurex Health, Inc, Myriad Genetics, Inc) 81291, 81479

GeneSight® MTHFR (Assurex Health, Inc, Myriad Genetics, Inc) 81291, 81479

GeneSight® Psychotropic Panel (Assurex Health, Inc, Myriad Genetics, Inc) 0345U

IDgenetix® Test, (Castle Biosciences, Inc) 0411U

Medication Management Neuropsychiatric Panel, (RCA Laboratory Services LLC d/b/a GENETWORx) 0392U

Mental Health DNA Insight™ Panel (Pathway Genomics) 81479, possibly 81225 (CYP2C19), 81226(CYP2D6), 81291(MTHFR)

Millennium PGTSM, (Millennium Health) Usually 81479, possible 81225 (CYP2C19), 81226 (CYP2D6), 81227 (CYP2C9), 81291 (MTHFR)

MindX One™ Blood Test - Anxiety (MindX Sciences™, Inc) 0437U

MindX Blood Test™ - Mood, (MindX Sciences™, Inc) 0291U
MindX Blood Test™ - Stress, (MindX Sciences™, Inc) 0292U
MindX Blood Test™ - Suicidality, (MindX Sciences™, Inc.) 0293U
MyGenVar Pharmacogenomics Test, (Geisinger Medical Laboratories) 0516U
Neuropharmagen® Test (Precision Genetics) 81479 possible 81418
PersonaGene Genetic Panels , (Astrea Health) Usually 81479, possible 81225 (CYP2C19), 81226 (CYP2D6), 81227 (CYP2C9), 81291 (MTHFR), 81418 (CYP2C19,CYP2D6 variants and duplication deletion)
PersonalisedRx, 81479, possible 81418 (CYP2C19,CYP2D6 variants and duplication deletion)
PrecisView® CNS (Phenomix Health Inc™) 0517U
Proove Addiction Profile, (Proove Biosciences, Inc) 81479
Proove Drug Metabolism Panel, (Proove Biosciences, Inc) 81479
Proove Narcotic Risk Panel, (Proove Biosciences, Inc) 81479
Proove Opioid Risk Assay, (Proove Biosciences, Inc) 81479, possible 81225 (CYP2C19), 81226(CYP2D6), 81227 (CYP2C9)
Proove Opioid-Induced Side Effects Profile, (Proove Biosciences, Inc) 81479
Proove Opioid Response Profile, (Proove Biosciences Inc) 81479
Proove Psychiatric Risk and Response Profile, (Proove Biosciences, Inc) 81479
Psych HealthPGx Panel, (RPRD Diagnostics) 0173U
RightMed® Comprehensive Test, (OneOme®, LLC) 0349U
RightMed® Gene Test Exclude F2 and F5, (OneOme® LLC) 0434U
RightMed® Gene Report, (OneOme® LLC) 0350U

- This code will require precertification review and may be covered for other indications such as CYP450 Genotyping for codeine, cerdelga, siponimod, and thiopurine drug response testing.

RightMed® Mental Health Gene Report, (OneOme®, LLC) 0476U
RightMed® Mental Health Medication Report (OneOme®, LLC) 0477U
RightMed® PGx16 Test, (OneOme®, LLC) 0347U
STA2R test, (SureGene Test for Antipsychotic and Antidepressant Response, SureGene LLC) 81479
SyncView® Pain (Phenomix Health™, Inc) 0518U
SyncView® PainPlus (Phenomix Health™, Inc) 0519U
SyncView® Rx (Phenomix Health™, Inc) 0520U
Tempus nP, (Tempus Labs, Inc) 0419U
UCSF Pharmacogenomics Panel (University of California San Francisco Genomic Medicine Laboratory) 0533U

CODING GUIDELINES

The American Medical Association (AMA) and Centers for Medicare and Medicaid Services (CMS) may update codes more frequently than the policy updates, therefore, codes that are not active on the date of service may not be eligible for reimbursement.

The following codes may be covered for other indications, but for the purpose of this policy, they are not covered if used in the tests identified in this policy.

81225	CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)
81226	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)
81227	CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)
81291	MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)
81418	Drug metabolism (eg, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion analysis
81479	Unlisted molecular pathology procedure
0093U	Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected
0173U	Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes
0175U	Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes
0291U	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score
0292U	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score
0293U	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score
0434U	Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes
0345U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6
0347U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes
0349U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions
0350U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes

0392U	Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6, reported as impact of gene-drug interaction for each drug
0411U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6
0419U	Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype
0423U	Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition
0437U	Psychiatry (anxiety disorders), mRNA, gene expression profiling by RNA sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score
0438U	Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene- drug interactions
0476U	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes
0477U	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes
0516U	Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status
0517U	Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications
0518U	Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications
0519U	Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LCMS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation
0520U	Therapeutic drug monitoring, 200 or more drugs or substances, LCMS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications
0533U	Drug metabolism (adverse drug reactions and drug response), genotyping of 16 genes (ie, ABCG2, CYP2B6, CYP2C9, CYP2C19, CYP2C, CYP2D6, CYP3A5, CYP4F2, DPYD, G6PD, GGCS, NUDT15, SLC01B1, TPMT, UGT1A1, VKORC1), reported as metabolizer status and transporter function

REFERENCES

- Aboelbaha et al. Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review. *Neuropsychiatr Dis Treat* 2021. 17:2397-419.
- Baum, M. L., Widge, A. S., Carpenter, L. L., McDonald, W. M., Cohen, B. M., Nemeroff, C. B., & American Psychiatric Association (APA) Workgroup on Biomarkers and Novel Treatments (2024). Pharmacogenomic Clinical Support Tools for the Treatment of Depression. *The American journal of psychiatry*, 181(7), 591–607. <https://doi.org/10.1176/appi.ajp.20230657>. Accessed April 16, 2026
- Bousman CA, Bengesser SA, Aitchison KJ, et al. Review and consensus on pharmacogenomic testing in psychiatry. *Pharmacopsychiatry*. 2021;54(1):5-17.
- Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., Brown, J. T., Bell, G. C., Leeder, J. S., Gaedigk, A., Scott, S. A., Klein, T. E., Caudle, K. E., & Bishop, J. R. (2023). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. *Clinical pharmacology and therapeutics*, 114(1), 51–68. <https://doi.org/10.1002/cpt.2903>
- CDC. Data Resources. Updated October 21, 2024. <https://www.cdc.gov/overdose-prevention/data-research/facts-stats/index.html>
- Fares-Otero NE, Budde M, Laatsch J, et al. Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis. *European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology*. 2025;100:13-23. PMID: 40889463
- "GeneSight Psychotropic (Assurex Health Inc./Myriad Neuroscience)." *Symplr Evidence Analysis. Molecular Test Assessment*. Annual review 17 Sep, 2024. <https://evidence.hayesinc.com/report/gte.genesight3945>
- "GeneSight Psychotropic (Myriad Neuroscience)." *Symplr Evidence Analysis. Precision Medicine Research Brief*. 23, Feb, 2026. <https://evidence.hayesinc.com/report/pmrb.genesight3945>
- Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. *Journal of psychiatric research*. 2019;111:59-67. PMID: 30677646
- Industry Standard Review
- InterQual® 2026, Mar. 2026 Release, BH:Behavioral Health Services: Pharmacogenomic Testing for Psychotropic Medication Drug Response. <https://prod.ds.interqual.com/caas/review/subsetSelect>. Last accessed 04/20/2026
- Optum Current Procedural Coding Expert CPT® codes with Medicare essentials for enhanced accuracy. 2024.
- "Pharmacogenomic Testing for Attention-Deficit/Hyperactivity Disorder Treatment." *Symplr Evidence Analysis. Clinical Utility Evaluation. Annual review 11, June, 2025*. <https://evidence.hayesinc.com/report/pmu.pharmoadhd5242>. Last accessed 04/16/2026
- "Pharmacogenetic and Pharmacogenomic Testing to Improve Outcomes Related to Opioid Use Disorder." *Symplr Evidence Analysis. Clinical Utility Evaluation*, 27 Apr. 2020, <https://evidence.hayesinc.com/report/gtu.opioiduse4837>. Last accessed 04/16/2026

"Pharmacogenomic Testing for Major Depressive Disorder." *Symplr Evidence Analysis. Clinical Utility Evaluation*. 09, May 2025. <https://evidence.hayesinc.com/report/gti.pharmacogenetics3715>

"Pharmacogenomic Testing for Schizophrenia Disorder." *Symplr Evidence Analysis. Clinical Utility Evaluation*, 29 Jul, 2025. <https://evidence.hayesinc.com/report/gtu.pharmacogeneticschizophrenia6114>.

"Pharmacogenetic and Pharmacogenomic Testing for Opioid Treatment for Pain in Adults – Selected Single-Gene Variants and Pharmacogenomic Panels." *Symplr Evidence Analysis. Clinical Utility Evaluation*, 11, Dec.2019, <https://evidence.hayesinc.com/report/gtu.opioid4759>. Last accessed 04/16/2026

"Pharmacogenetic Testing for Opioid Treatment for Pain – OPRM1 and COMT Variants." *Symplr Evidence Analysis. Clinical Utility Evaluation*, 24, Oct. 2022. <https://evidence.hayesinc.com/report/gtu.oprm1variant4758>. Last accessed 04/17/2026

The American Academy of Child & Adolescent Psychiatry. Clinical Use of Pharmacogenetic Tests in Prescribing Psychotropic Medications for Children and Adolescents. [cited 9/18/2025]. 'Available from:' https://www.aacap.org/AACAP/Policy_Statements/2020/Clinical-Use-Pharmacogenetic-Tests-Prescribing-Psychotropic-Medications-for-Children-Adolescents.aspx.

"The RightMed Test (OneOme LLC)." Precision Medicine Research Brief. 25, March, 2024. <https://evidence.hayesinc.com/report/pmr.rightmed5804>. Last accessed 04/16/2026

"UpToDate." *Uptodate.com*, 2026, https://www.uptodate.com/contents/major-depressive-disorder-in-adults-initial-treatment-with-antidepressants?search=pharmacogenomics%20behavioral%20health%20&source=search_result&selectedTitle=7~150&usage_type=default&display_rank=7. Last accessed 04/20/2026

U. S. Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. Available from: <http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm>

Wang X, Wang C, Zhang Y, An Z. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: A systematic review and meta-analysis of RCT. *BMC Psychiatry*. 2023;23(1):334

RELATED POLICIES

Proprietary Laboratory Testing - Policy Stat ID 16843887

POLICY HISTORY

07/01/2026 New

DISCLAIMER

CPT codes are copyright of the American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

The services listed in this policy is not meant to be an all-inclusive list of genetic, pharmacogenetic, and pharmacodynamic testing services available. Codes not found in this policy do not necessarily imply coverage or non-coverage of a service.

This policy is intended to serve as a guideline only and does not constitute medical advice, any guarantee of payment, plan pre-authorization, an explanation of benefits, or a contract. This policy is intended to address

medical necessity guidelines that are suitable for most individuals. Each individual's unique clinical situation may warrant individual consideration based on medical records. Individual claims may be affected by other factors, including but not necessarily limited to state and federal laws and regulations, legislative mandates, provider contract terms, and THP's professional judgment. Reimbursement for any services shall be subject to member benefits and eligibility on the date of service, medical necessity, adherence to plan policies and procedures, claims editing logic, provider contractual agreement, and applicable referral, authorization, notification, and utilization management guidelines. Unless otherwise noted within the policy, THP's policies apply to both participating and non-participating providers and facilities. THP reserves the right to review and revise these policies periodically as it deems necessary in its discretion, and it is subject to change or termination at any time by THP. THP has full and final discretionary authority for its interpretation and application. Accordingly, THP may use reasonable discretion in interpreting and applying this policy to health care services provided in any particular case.

No part of this policy may be reproduced, stored in a retrieval system, transmitted, in any shape or form or by any means, whether electronic, mechanical, photocopying, or otherwise, without express written permission from THP. When printed, this version becomes uncontrolled. For the most current information, refer to the following website: healthplan.org.

COPY